NCT02048020View on ClinicalTrials.gov

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 26, 2013

Primary Completion Date

January 9, 2017

Study Completion Date

January 9, 2017

Conditions
Human Papilloma Virus InfectionStage III Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the LarynxStage III Squamous Cell Carcinoma of the OropharynxStage III Verrucous Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Verrucous Carcinoma of the LarynxStage IVA Squamous Cell Carcinoma of the LarynxStage IVA Squamous Cell Carcinoma of the OropharynxStage IVA Verrucous Carcinoma of the LarynxStage IVB Squamous Cell Carcinoma of the LarynxStage IVB Squamous Cell Carcinoma of the OropharynxStage IVB Verrucous Carcinoma of the LarynxStage IVC Squamous Cell Carcinoma of the LarynxStage IVC Squamous Cell Carcinoma of the OropharynxStage IVC Verrucous Carcinoma of the Larynx
Interventions
DRUG

paclitaxel

Given IV

DRUG

carboplatin

Given IV

RADIATION

intensity-modulated radiation therapy

Undergo IMRT

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (1)

90095

Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT02048020 - Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer | Biotech Hunter | Biotech Hunter